Frankfurt - Delayed Quote EUR

Champions Oncology, Inc. (2I3.F)

5.15

0.00

(0.00%)

As of May 2 at 3:29:01 PM GMT+2. Market Open.

Champions Oncology Obtains Radioactive Materials License to Advance Comprehensive Radiotherapeutic Studies In-House

HACKENSACK, NJ / ACCESS Newswire / April 28, 2025 / Champions Oncology (NASDAQ:CSBR), a leader in translational oncology research, has been granted a license to use radioactive materials in preclinical studies. This approval allows in-house work utilizing ...

ACCESS Newswire 6 days ago

CSBR
-9.56%
Champions Oncology's Data Platform Gains Momentum through a Strategic Collaboration with Turbine

HACKENSACK, NJ / ACCESS Newswire / April 24, 2025 / Champions Oncology (NASDAQ:CSBR), a global leader in oncology R&D solutions, has announced a strategic collaboration with Turbine, the creators of the world's first interpretable cell simulation ...

ACCESS Newswire 10 days ago

CSBR
-9.56%
Champions Oncology Inc (CSBR) Q3 2025 Earnings Call Highlights: Record Revenue and Strategic ...

Champions Oncology Inc (CSBR) reports a transformative quarter with record revenue, strategic data deals, and a focus on AI-driven opportunities despite sector challenges.

GuruFocus.com 13 days ago

CSBR
-9.56%
Champions Oncology's (NASDAQ:CSBR) investors will be pleased with their respectable 47% return over the last year

Champions Oncology, Inc. ( NASDAQ:CSBR ) shareholders have seen the share price descend 23% over the month. But that...

Simply Wall St. 21 days ago

CSBR
-9.56%
Champions Oncology Third Quarter 2025 Earnings: EPS: US$0.33 (vs US$0.19 loss in 3Q 2024)

Champions Oncology ( NASDAQ:CSBR ) Third Quarter 2025 Results Key Financial Results Revenue: US$17.0m (up 42% from 3Q...

Simply Wall St. last month

CSBR
-9.56%
Champions Oncology Reports Record Quarterly Revenue of $17.0 Million Record Net Income of $4.5 Million

HACKENSACK, NJ / ACCESS Newswire / March 11, 2025 / Champions Oncology, Inc. (Nasdaq:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, today announced its financial results for its third ...

ACCESS Newswire last month

CSBR
-9.56%
Champions Oncology to Announce Third Quarter Financial Results on Tuesday, March 11, 2025

HACKENSACK, NJ / ACCESS Newswire / March 6, 2025 / Champions Oncology, Inc. (NASDAQ:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, will report its financial and operational results for ...

ACCESS Newswire last month

CSBR
-9.56%
We're Interested To See How Champions Oncology (NASDAQ:CSBR) Uses Its Cash Hoard To Grow

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Simply Wall St. last month

CSBR
-9.56%
Champions Oncology Announces 17 Abstracts Accepted for Presentation at the 2025 American Association for Cancer Research Annual Meeting

HACKENSACK, NJ / ACCESS Newswire / February 18, 2025 / Champions Oncology Inc. (NASDAQ:CSBR), a global leader in preclinical oncology research and clinical specialty testing, today announced the acceptance of seventeen abstracts for presentation at ...

ACCESS Newswire 2 months ago

CSBR
-9.56%
Schrodinger Stock Scores IBD Rating Upgrade

Schrodinger shows improving price performance, earning an upgrade to its IBD Relative Strength Rating

Investor's Business Daily 2 months ago

CSBR
-9.56%

NTRA

SDGR
A Look At The Intrinsic Value Of Champions Oncology, Inc. (NASDAQ:CSBR)

Key Insights Champions Oncology's estimated fair value is US$10.12 based on 2 Stage Free Cash Flow to Equity Champions...

Simply Wall St. 3 months ago

CSBR
-9.56%
Champions Oncology integrates Cytek Aurora flow cytometers

Champions Oncology (CSBR) announced advancements in its bioanalytical services portfolio, specifically, expanding its capabilities with the integration of multiple global Cytek Aurora flow cytometers and the appointment of Troy Tremaine, MBA, to spearhead Bioanalytical Commercial Strategy. The addition of Cytek Aurora instruments elevates Champions’ service offerings, building on its already competitive spectral and conventional flow cytometry capabilities. The continued investment in this clini

TipRanks 3 months ago

CSBR
-9.56%
Champions Oncology Enhances Clinical Bioanalytical Services Portfolio with New Technology and Additional Leadership

Champions Oncology, Inc. (NASDAQ:CSBR), a leading technology-enabled oncology research organization with specialty testing services, is excited to announce significant advancements in its bioanalytical services portfolio, specifically, expanding its ...

ACCESS Newswire 3 months ago

CSBR
-9.56%
Private equity firms invested in Champions Oncology, Inc. (NASDAQ:CSBR) up 19% last week, insiders too were rewarded

Key Insights Significant control over Champions Oncology by private equity firms implies that the general public has...

Simply Wall St. 4 months ago

CSBR
-9.56%
Champions Oncology Reports Quarterly Revenue of $13.5 Million Adjusted EBITDA of $1.1 Million

Champions Oncology, Inc. (Nasdaq:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, today announced its financial results for its second quarter of fiscal 2025, ended October 31, 2024. Second ...

ACCESS Newswire 4 months ago

CSBR
-9.56%
Champions Oncology to Announce Second Quarter Financial Results on Wednesday, December 11, 2024

HACKENSACK, NJ / ACCESSWIRE / December 5, 2024 / Champions Oncology, Inc. (NASDAQ:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, will report its financial and operational results for ...

ACCESS Newswire 4 months ago

CSBR
-9.56%
Champions Oncology (NASDAQ:CSBR) shareholders have endured a 61% loss from investing in the stock three years ago

Investing in stocks inevitably means buying into some companies that perform poorly. But the long term shareholders of...

Simply Wall St. 5 months ago

CSBR
-9.56%
Champions Oncology Announces Agreement with Weill Cornell Medicine

HACKENSACK, NJ / ACCESSWIRE / October 16, 2024 /Champions Oncology, Inc. (Nasdaq:CSBR), a leader in the development of advanced preclinical oncology solutions, is pleased to announce a licensing agreement with Weill Cornell Medicine through the Center ...

ACCESS Newswire 6 months ago

CSBR
-9.56%
Champions Oncology Inc (CSBR) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ...

Champions Oncology Inc (CSBR) reports a 12% revenue increase and improved operational efficiencies, despite facing external market pressures and funding challenges.

GuruFocus.com 6 months ago

CSBR
-9.56%
Champions Oncology Inc (CSBR) Q4 2024 Earnings Call Highlights: Navigating Challenges and ...

Despite a challenging fiscal year, Champions Oncology Inc (CSBR) shows signs of recovery with improved Q4 performance and strategic operational enhancements.

GuruFocus.com 6 months ago

CSBR
-9.56%

Performance Overview

Return	2I3.F	S&P 500 (^GSPC)
YTD	+8.19%	-3.31%
1-Year	+14.96%	+12.29%
3-Year	-28.47%	+36.85%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Champions Oncology, Inc. (2I3.F)

Champions Oncology Obtains Radioactive Materials License to Advance Comprehensive Radiotherapeutic Studies In-House

Champions Oncology's Data Platform Gains Momentum through a Strategic Collaboration with Turbine

Champions Oncology Inc (CSBR) Q3 2025 Earnings Call Highlights: Record Revenue and Strategic ...

Champions Oncology's (NASDAQ:CSBR) investors will be pleased with their respectable 47% return over the last year

Champions Oncology Third Quarter 2025 Earnings: EPS: US$0.33 (vs US$0.19 loss in 3Q 2024)

Champions Oncology Reports Record Quarterly Revenue of $17.0 Million Record Net Income of $4.5 Million

Champions Oncology to Announce Third Quarter Financial Results on Tuesday, March 11, 2025

We're Interested To See How Champions Oncology (NASDAQ:CSBR) Uses Its Cash Hoard To Grow

Champions Oncology Announces 17 Abstracts Accepted for Presentation at the 2025 American Association for Cancer Research Annual Meeting

Schrodinger Stock Scores IBD Rating Upgrade

A Look At The Intrinsic Value Of Champions Oncology, Inc. (NASDAQ:CSBR)

Champions Oncology integrates Cytek Aurora flow cytometers

Champions Oncology Enhances Clinical Bioanalytical Services Portfolio with New Technology and Additional Leadership

Private equity firms invested in Champions Oncology, Inc. (NASDAQ:CSBR) up 19% last week, insiders too were rewarded

Champions Oncology Reports Quarterly Revenue of $13.5 Million Adjusted EBITDA of $1.1 Million

Champions Oncology to Announce Second Quarter Financial Results on Wednesday, December 11, 2024

Champions Oncology (NASDAQ:CSBR) shareholders have endured a 61% loss from investing in the stock three years ago

Champions Oncology Announces Agreement with Weill Cornell Medicine

Champions Oncology Inc (CSBR) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ...

Champions Oncology Inc (CSBR) Q4 2024 Earnings Call Highlights: Navigating Challenges and ...

Performance Overview